Shares of aTyr Pharma Inc (NASDAQ:LIFE) saw unusually-high trading volume on Thursday . Approximately 2,632,427 shares traded hands during trading, an increase of 590% from the previous session’s volume of 381,437 shares.The stock last traded at $0.39 and had previously closed at $0.38.
LIFE has been the subject of a number of recent research reports. William Blair reissued a “market perform” rating on shares of aTyr Pharma in a research note on Tuesday, March 26th. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Friday, March 29th. Finally, ValuEngine raised shares of aTyr Pharma from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. aTyr Pharma presently has an average rating of “Hold” and an average price target of $1.01.
The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.00 and a current ratio of 4.00.
aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Monday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.05.
An institutional investor recently raised its position in aTyr Pharma stock. Viking Global Investors LP raised its position in aTyr Pharma Inc (NASDAQ:LIFE) by 131.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,209,955 shares of the biotechnology company’s stock after purchasing an additional 1,825,655 shares during the period. Viking Global Investors LP owned approximately 8.79% of aTyr Pharma worth $1,766,000 as of its most recent filing with the SEC. 30.44% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2019/06/15/atyr-pharma-nasdaqlife-sees-large-volume-increase.html.
aTyr Pharma Company Profile (NASDAQ:LIFE)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
See Also: What is a support level?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.